Protocol Ledger

NCT03972709 · Phase II · TERMINATED

A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

Interventional Phase II clinical trial protocol NCT03972709 sponsored by Roche / Genentech in Ophthalmology and Sensory, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-06-03 Enrollment: 372 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03972709
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)372 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03972709
Protocol FieldVerified Registry Value
NCT IdentifierNCT03972709
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortOphthalmology and Sensory
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment372 participants (ACTUAL)
Registered Start Date2019-06-03
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03972709
Hospital Research SiteLocationSite Profile
California Retina ConsultantsBakersfield, CAOpen Hospital Dossier ->
Retina Vitreous Associates Medical GroupBeverly Hills, CAOpen Hospital Dossier ->
The Retina PartnersEncino, CAOpen Hospital Dossier ->
Retina Consultants of Orange CountyFullerton, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Ophthalmology and Sensory Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI